Johnson & Johnson is collaborating with Advanced Materials and BioEngineering Research to establish a 3-D bioprinting laboratory. Work on the new laboratory will begin in the first quarter of 2018.
Here are six things to know:
1. AMBER is the Science Foundation Ireland-funded materials science institute headquartered at Trinity College Dublin in Ireland.
2. AMBER and the J&J 3D Printing Center of Excellence will establish the new Global Centre of Excellence for 3-D bioprinting at Trinity College. 3-D bioprinting can be used to engineer "living" biological tissues for promoting bone and tissue regeneration.
3. Trinity engineering professor and Trinity Centre for Bioengineering Director Daniel Kelly, PhD, and J&J bioprinting senior fellow Joseph Ault will co-lead the laboratory.
4. The laboratory will be located in a 100-square-meter space in the Trinity Biomedical Science Institute building suitable for working with bioprinting, cell and tissue culture. It will have meeting and office space for 12 people.
5. Other principal investigators, post-graduate and graduate students may carry out work at the laboratory outside direct collaboration with Dr. Kelly. J&J scientists will provide training and education to students and staff. The collaboration will allow for individual research projects and longterm scale-ups to include adjunct professorships and staff exchange.
6. "Building on our long-standing collaboration with DePuy Synthes in Ireland, I am confident that this engagement will become the prototypical strategic partnership for AMBER as the Centre moves into the next funding cycle," said AMBER Director Michael Morris, PhD. "Our intent is to identify and grow similar engagements of equivalent scale and type across the ICT and manufacturing sectors."
More articles on biologics:
Bone Therapeutics completes recruitment for spinal fusion study: 4 things to know
Positive clinical trial results for human dermal fibroblast injection CybroCell: 7 key insights
Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights